Diabetes changes the half-life and bioavailability of drugs through an overall increase in CYP enzymes due to a significant increase in total hepatic CYP content [7] accompanied by alterations in the CYP isozyme expression [8,9]. This evidence concerns the gene PPIG and diabetes mellitus.